Multidimensional Analysis of Bronchoalveolar Lavage Cytokines and Mast Cell Proteases Reveals Interferon-γ as a Key Biomarker in Equine Asthma Syndrome

Jane S. Woodrow, DVM, MS, DACVIM[1,2]; Melissa Hines, DVM, PhD, DACVIM[3]; Carla Sommardahl, DVM, PhD, DACVIM[3]; Bente Flatland, DVM, MS, DACVP, DACVIM[4]; Kaori U. Davis, DVM[5]; Yancy Lo, PhD[6]; Zhiping Wang, PhD[6]; Mary Katherine Sheats, DVM, PhD, DACVIM[5;] Elizabeth M. Lennon, DVM, PhD, DACVIM[2*]

1. Department of Comparative & Experimental Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, 37996
2. Department of Clinical Sciences and Advanced Medicine, College of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104
3. Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, 37996
4. Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, 37996
5. Department of Clinical Sciences, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 27607
6. Bioinformatics Core, Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA, 19104

*Address correspondence to mlennon@vet.upenn.edu (EML)

Abstract

Naturally-occurring equine asthma is an inflammatory lung disease characterized by chronic, partially reversible airway obstruction, pulmonary remodeling and lower airway inflammation. The cytokine profiles that

26 distinguish asthma groups or subtypes in horses have not been systematically classified, and mast cell

27 phenotypes, which, in human asthma, correlate with asthma type, lung function, and response to therapy, have

28 not been well-described in horses. The purpose of this study was to: (1) compare mast cell protease mRNA

29 expression between healthy and asthmatic horses, (2) analyze the cytokine profile present in BALF of currently

30 defined equine asthma groups, and (3) use these data to evaluate potential biomarkers of defined asthma groups.

31 Mast cell protease gene expression and select cytokine gene expression in cells isolated from BALF, and BALF

32 multiplex cytokine assays were performed. Multidimensional analysis demonstrated that IFNγ differentiates

33 severe from moderate asthma, and that TNFα and CXCL8 are key biomarkers of equine asthma subtype.

34 Expression of chymase mRNA, a mast cell-specific protease, was significantly decreased in horses with

35 mastocytic asthma. These results will help further define EAS immunopathology, which could improve

36 understanding and definitions of asthma groups, while also potentially identify novel therapeutic strategies.

37 **Introduction**

38   Equine asthma is a chronic inflammatory lung disease characterized by enhanced bronchial reactivity,

39 and chronic, partially reversible airflow obstruction, pulmonary remodeling, and lower airway inflammation [1].

40 The most common environmental triggers for asthma development in susceptible horses include pollens, dust,

41 mold, and bacterial components. Equine asthma prevalence in the Northern hemisphere is about 14% and the

42 disease can be frustrating to manage, while also being career or life ending for the horse [2, 3]. Recently it has

43 also been shown that prevalence can change with season [4]. The diagnosis is based on history, physical

44 examination, bronchoalveolar lavage fluid (BALF) cytology, and lung function tests. Lung function tests are

45 performed less frequently due to cost, required skill for equipment use and data analysis, and availability of the

46 apparatus. History and physical exam findings supporting asthma include clinical signs of lower airway

47 inflammation, such as cough, increased respiratory rate and effort, poor performance/exercise intolerance, and

48 serous, mucoid, or mucopurulent nasal discharge at rest and/or at exercise. A 2016 consensus statement has

49 defined two categories of equine asthma syndrome (EAS), currently designated as mild to moderate asthma

50 (mEAS) and severe asthma (sEAS) [1]. For horses with sEAS, auscultation of the lungs at rest or during

51 rebreathing exam can reveal wheezes, crackles, cough, and/or tracheal rattle. Abnormalities upon auscultation

52 may not be apparent, but recovery from a rebreathing exam may be prolonged in mEAS or sEAS horses. In

53 contrast to horses with sEAS, horses with mEAS do not have clinical signs at rest [1]. BALF cytological

54 findings supporting asthma include an increased percentage of neutrophils (most pronounced in severe asthma),

55 mast cells, eosinophils, or some combination of increase in these cells.

56   In both horses and humans, asthma immune response phenotypes have been broadly divided into

57 allergic asthma, with a Th2-high immune response, and non-allergic asthma, with a non-Th2 immune response.

58 However, the two phenotypes are not always clearly defined as such and can include horses from both mEAS

59 and sEAS group [5]. A Th1 immune response has been shown to be associated with a generalized increase in

60 BALF cell numbers in lower airway inflammation, although cytokine profiles, either at the protein or mRNA

61 level, may support more of a Th1, Th2, Th17, or mixed immune response, depending on the study [6-17].

62 Additionally, the extent of airway remodeling and collagen deposition has been linked to the balance of

63 transforming growth factor (Tgf)-β1 and bone morphogenetic protein (BMP)-7 in human and mouse asthma

64 [18-20]. One report in horses notes no significant differences in Tgfβ1, but has not been followed up, nor has

65 BMP7 been investigated [21]. Due to inconsistencies in reported cytokine profiles and focusing on a single

66 category of EAS, this has limited our ability to fully describe the pathogenesis of EAS and its categories, which

67 ultimately limits our diagnostic, treatment, and management abilities.

68   Asthma in people is additionally described by the type of inflammatory cells present in the airways [22-

69 24]. Recently, the presence of mast cells in human asthmatics' BALF and induced sputum samples has been

70 shown to correlate with asthma type and response to therapy [25-27]. In humans, two main phenotypes of mast

71 cells are recognized based on the proteases they contain; tryptase-only containing mast cells (MC_T), and

72 tryptase, chymase, and carboxypeptidase A3 containing mast cells (MC_{TC}) [28, 29]. Healthy human lungs

73 predominantly contain mast cells of the mucosal-type (MC_T), and asthma is associated with an increase in MC_T

74 and/or the connective tissue-type (MC_{TC}) depending of asthma type [25, 30]. Cytological identification of mast

75 cells in induced human sputum is difficult due to low cell prevalence; therefore, protease mRNA expression is

76 used. Using this technique, a third mast cell type with increased tryptase and carboxypeptidase A3, but

77 decreased chymase expression was identified in human asthmatics that correlated with eosinophilic asthma and

78 increased responsiveness to corticosteroids [26, 27]. Mast cell lung phenotypes identified in humans have not

79 been thoroughly evaluated in horses, but warrant further investigation as they are limited to tissue samples [31,

80 32].

81   We hypothesized that healthy and asthmatic horses would have significantly different BALF mast cell

82 protease mRNA expression and cytokine/chemokine levels that would correlate with BALF cytology results

83 and health status. The objectives of this study were to: (1) compare mast cell protease mRNA expression

84 between healthy and asthmatic horses, (2) analyze the cytokine profile present in BALF of currently defined

85 equine asthma groups, and (3) use these data to evaluate potential biomarkers of defined asthma groups.

86

87 **Results**

88 *Main study population – University of Tennessee College of Veterinary Medicine (UT-CVM)*

89   A total of 54 horses were sampled for evaluation. Twenty horses were excluded because they did not

90 meet our inclusion criteria (see **Table 1 and Supplementary Table S3**). Final groups were comprised of 11

91 healthy and 23 asthmatic horses (9 mild/moderate and 14 severe) (see **Supplementary Table S1 and S2**

92 **online)**. Median age was not significantly different between groups. Various breeds were represented in each

93 group.

94 *Sub-population – North Carolina State University College of Veterinary Medicine (NCSU-CVM)*

95   Samples from 8 horses with mastocytic asthma (maEAS) sampled at NCSU were included to fully

96 evaluate mast cell protease expression due to the lack of mast cells detected in UT-CVM asthma cohort (see

97 **Table 1, Supplementary Table S1, and S2 online**). Although the ages of some of the horse were unknown, the

98 median age of the NCSU-CVM group was not significantly different from the UT-CVM groups.

99

100 **Table 1.** Diagnostic Criteria for Experimental Groups.

Experimental Group	History & Physical exam	CBC/fibrinogen	BALF cytology
Healthy *Main population* *UT-CVM*	Normal	Normal	≤6% neutrophils, ≤1% eosinophils, ≤2% metachromatic cells, and ≤50% lymphocytes
Asthma *Main population* *UT-CVM*	History, clinical signs, and physical exam supportive of lower airway inflammation; no changes to or initiation of corticosteroids (systemic or intranasal) within 2 weeks of enrollment	Not consistent with systemic infection	≥10% neutrophils, ≥5% mast cells, and/or ≥5% eosinophils *severe asthma, >25% neutrophils
Mastocytic Asthma *Sub-population* *NCSU-CVM*	History, clinical signs, and physical exam supportive of lower airway inflammation; no corticosteroids administered within 2 weeks of BAL	Not performed	≥2% mast cells ≤6% neutrophils ≤1% eosinophils

101

102

BALF Cell Count and Cytologic Analysis (UT & NCSU-CVM)

Results of BALF cell count and cytological analysis are described in **Table 2** and **Supplementary Table S2**. The median total nucleated cell count (TNCC) of each group was not statistically different, although 5 outliers in the sEAS group had TNCC > 1,000 cell/µL. As expected, based on standard diagnostic criteria, horses with severe asthma had significantly higher percentages of neutrophils compared to healthy horses and those with maEAS ($p < 0.0001$ & $p = 0.0002$, respectively). Horses with sEAS had lower percentages of lymphocytes in their BALF when compared to mEAS or those with maEAS ($p < 0.0001$ & $p = 0.0009$, respectively). The composition of immune cells in healthy horses was predominated by macrophages compared to sEAS ($p < 0.0001$). Three horses with mEAS had BALF eosinophilia with ≥ 5% eosinophils. No eosinophils were detected in BALF from any healthy horses or horses with sEAS. Mast cells were only detected in maEAS horses with a median mast cell percentage of 5.0 [interquartile range (IQR): 4.18 – 5.75%].

Table 2

| Group	TNCC (cell/µL)	%				
		N	L	M	E	MC
sEAS	500 [257 – 3775]	83.0[*‡] [57.0 – 94.0]	10[*‡] [1 – 26.5]	6.5[*‡] [4.5 – 16.5]	0	0
mEAS	250 [150 – 425]	12.0[‡] [4.5 – 17.0]	50[*] [34.5 – 56.5]	36 [28.5 – 54.5]	1.0 [0.0 – 5.0]	0
Ctr	250 [200 – 300]	1.0[*] [1.0 – 3.0]	30 [24 – 4]	68[*] [56 – 75]	0	0
maEAS	291.5 [169.5 – 355.8]	2.35 [1.18 – 5.03]	47.65[‡] [22 – 58.73]	46[‡] [28.2 – 70.5]	0.0 [0.0 – 0.7]	5.0 [4.18 – 5.75]

115 *sEAS= Severe Asthma, mEAS= Mild/Moderate Asthma, maEAS= Mastocytic Asthma, Ctr= Healthy; TNCC=

116 Total Nucleated Cell Count (Average recorded); N= neutrophil, L= lymphocyte, M= macrophage, E=

117 eosinophil, MC= mast cell. Note: Medians in the same column with the same superscript symbol differ

118 significantly from each other.

119

120

121 *Mast cell protease gene expression in BALF (UT & NCSU-CVM)*

122 In order to determine whether mast cells have altered protease phenotypes in equine asthma, gene

123 expression analysis was performed on 37 horses (see **Fig. 1** and **Supplementary Table S4 online**). Samples

124 from five horses (4 sEAS, 1 mEAS) were excluded due to poor quality and/or concentrated RNA. Analysis of

125 protease gene expression in BALF isolated cells revealed that chymase was significantly lower in horses with

126 maEAS (fold change: 0.18 [0.08 – 0.54]) than control (1.88 [0.33 – 2.46]; $p < 0.05$), or sEAS horses (0.92 [0.65

127 – 1.97]; $p < 0.05$), implying that mast cell protease expression is altered in horses with mastocytic

128 inflammation. As expected, CD117(ckit), expression was significantly increased in horses with maEAS (fold

129 change: 2.32, [1.31 – 3.85]) compared to sEAS (0.38 [0.27 – 1.50]; $p < 0.05$). Tryptase expression appeared

130 slightly higher in horses with maEAS compared to sEAS, but was not statistically different between any groups.

131 Additionally, carboxypeptidase A3 was not amplified in any sample, with either primer set identified, but

132 whether this was due to a technical issue or lack of carboxypeptidase A3 gene expression has not been

133 determined.

134   **Figure 1**

135   **(a)**

136

137

138   **(b)**

139

140

141   **(c)**

Chymase

142

143

144   *Multiplex Bead Immunoassay Analysis (Interleukin [IL]-2, IL-4, IL-5, IL-17A, CXC motif chemokine ligand*

145   *[CXCL]8, Interferon [IFN]γ, Tumor Necrosis Factor [TNF]α) (UT-CVM)*

146   Evaluation of BALF cytokine concentrations was only performed in the UT-CVM study population for

147   consistency of the BALF procedure (see **Table 3, Fig. 2, and Supplementary Table S5 online**). Significant

148   differences between groups were found for TNFα, CXCL8 (formerly known as IL-8), and IFNγ. BALF

149   multiplex showed that horses with asthma had significantly higher TNFα (mEAS: $p < 0.05$; sEAS: $p < 0.001$)

150   concentrations compared to healthy horses as well as significantly elevated CXCL8 (mEAS: $p < 0.05$; sEAS:

151   $p<0.0001$), concentrations compared to healthy horses. Additionally, IFNγ was significantly elevated in sEAS

152   compared to healthy horses ($p < 0.05$). There were no statistical differences in cytokine concentrations between

153   horses with mEAS or sEAS. No significant differences between groups were found for the remaining analytes.

154   Spike and recovery was lowest for IL-17A and high at low concentrations for IL-4 and TNFα (see

155   **Supplementary Table S6)**. Dilutional linearity was achieved for all analytes (see **Supplementary Fig. S1)**.

9

156   **Table 3**

| Group	IL-5 pg/mL	IL-17A pg/mL	IL-2 pg/mL	IL-4 pg/mL	IFNγ pg/mL	CXCL8 pg/mL	TNFα pg/mL
sEAS	0.99 [0.5 – 1.98]	Not detected	0.46 [0.44 – 0.63]	16.35 [16.35 – 16.35]	35.28* [21.08 – 75.45]	19.83* [16.86 – 27.82]	11.31* [3.67 – 21.77]
mEAS	1.05 [0.72 – 3.95]	Not detected	0.44 [0.44 – 1.32]	16.35 [16.35 – 24.16]	28.87 [21.08 – 77.64]	14.41‡ [8.74 – 22.48]	6.54‡ [4.79 – 7.69]
Ctr	0.5 [0.5 – 0.99]	Not detected	0.44 [0.44 – 0.44]	16.35 [16.35 – 16.35]	21.08* [21.08 – 21.08]	4.54*‡ [1.26 – 8.88]	2.0*‡ [0.8 – 3.63]

157   Note: Medians in the same column with the same superscript symbol differ significantly from each other.

158   **Figure 2**

159   **(a)**

160

161

162   **(b)**


163

10

164

165 **(c)**

166

167

168

169 *Analysis of Similarity Between Samples (UT-CVM)*

170 Pairwise correlation analysis of the variables demonstrated a moderate positive correlation between

171 neutrophil percentage and CXCL8, TNFα, and IFNγ concentrations (Pearson's r = 0.54, 0.47, 0.35,

172 respectively) (see **Fig. 3**). The gene expression fold change of CD117(ckit) was positively correlated with

173 tryptase (r = 0.94).

174 **Figure 3**

175

176

177   Multidimensional scaling (MDS) analysis showed separation between samples from horses with sEAS,

178 mEAS, and healthy horses (see **Fig. 4A**). The healthy samples and mEAS samples did not form distinct clusters,

179 but a gradual trend from healthy to mEAS to sEAS was observed on both axes of the two-dimensional

180 projection. Further principal component analysis on samples with complete data showed that the first two

181 principal components (PCs) explained over 98.5% of the variance, with the first PC explaining over 95% of the

182 variance. The absolute value of the loadings of the first two PCs quantified the contribution of each variable to

183 the observed clustering pattern. By ranking the variables on the maximum absolute loadings from PC1 and PC2,

184 IFNγ concentration and neutrophil percentage were the main drivers of the observed clusters (see **Fig. 4B**).

Figure 4

(a)

**(b)**

191

192

193   *Analysis of BMP7 and Tgfβ1 expression (UT & NCSU-CVM)*

194   Potential equine airway remodeling cytokines, BMP7 and Tgfβ1, were evaluated in BALF isolated cells.

195   BMP7 expression in BALF derived cells was not significantly different across the groups, although a subset of

196   horses diagnosed with sEAS had markedly elevated BMP7 expression (see **Fig. 5** and **Supplementary Table**

197   **S4**). Tgfβ1 was significantly elevated in mEAS (fold change: 1.54, [1.16 – 1.73,] p=0.02) versus healthy (fold

198   change: 1.06, [0.81 – 1.22]). Tgfβ1 to BMP7 ratios did not explain the subgrouping of sEAS seen in BMP7

199   expression results, although 3 horses in the sEAS group (1 in low BMP7, 2 in high BMP7) were unable to have

200   Tgfβ1 analyzed due to lack of remaining RNA for analysis.

201   **Figure 5**

202   **(a)**

203

14

204   **(b)**

205

206   **(c)**

207

208

209

210   **Discussion**

211   This study, to our knowledge, is the first to examine BALF supernatant cytokine/chemokine

212   concentrations at the protein level, and mast cell protease expression in cells isolated from BALF in horses with

213   asthma. We utilized an unbiased approach and multidimensional scaling to integrate clinical data, cytokine and

214   chemokine concentrations, and mast cell protease expression, in order to investigate the most important

215   biomarkers of equine asthma. This analysis indicated that IFNγ is a key biomarker of equine asthma, in

216   particular, severe equine asthma. Similarly, in BALF cells isolated from humans with severe asthma, IFNγ

217   expression was increased compared to mild/moderate asthma, and further mechanistic analysis of the IFNγ

218   pathway in a mouse model demonstrated that IFNγ dysregulation was the main cause of airway hyper-

219   responsiveness via regulation of the epithelial cell-expressed protein *SLPI* (Secretory Leukocyte Peptidase

220   Inhibitor), which downregulates airway reactivity [33]. In addition to airway hyper-responsiveness, airway

221   remodeling is another key feature of asthma. Tgfβ1 and BMP7 expression in asthma models and human asthma

222   highlights their balance as an important factor in asthma airway remodeling [18-20]. This study is the first to

223   evaluate BMP7 expression in the airway of the horse. Our results demonstrated that a subset of horses with

224   sEAS had elevated BMP7 expression compared to all other groups. BMP7 is a cytokine in the TGFβ

225   superfamily that has both anti-inflammatory and anti-fibrotic effects. The potential role of BMP7 in human

226   asthma has been suggested to be anti-inflammatory, with BMP7's ability to block detrimental Tgfβ1effects,

227   such as fibroblast activation with subsequent airway remodeling, production of extracellular matrix, and

228   collagen deposition [19, 20]. The sEAS BMP7-high group may have an over exuberant BMP7 response in

229   attempt to counteract airway remodeling. Airway function tests may be worse in the sEAS BMP7 high subset of

230   horses and have less reversible airway obstruction. Further studies to define the horses with BMP7-high and

231   BMP-7 low sEAS may elucidate further subgroupings of sEAS and further define the pathophysiology.

232   In this study, cytokine/chemokine concentrations in BALF in the main study population (UT-CVM),

233   revealed elevated TNFα and CXCL8 in both mEAS and sEAS horses; therefore, these are potential targets for

234   treatment in asthma. Elevated TNFα and CXCL8 parallels findings in human asthma, in which asthmatics had

235   increased TNFα and CXCL8 versus control, and neutrophilic asthma was associated with further increased

236   CXCL8 [34, 35]. Additionally, sEAS clustered separately from the other groups based on increased IFNγ and

237   neutrophil percentage, therefore they appear to be the best targets for modulation during exacerbation of severe

238   asthma.

239   We additionally demonstrated that mast cell protease expression is altered in horses with mastocytic

240   asthma, in particular, that chymase is reduced. Loss of chymase may contribute to disease progression since

241   chymase has anti-inflammatory activities in allergic asthma models via modulating IL-33 concentrations, and

242   may be protective of lung function [36, 37]. In contrast, mast cell protease expression is relatively unchanged in

243   mEAS and sEAS. We also demonstrated that mast cells in equine BALF express both tryptase and chymase

244   mRNA. Whether equine mast cells also express carboxypeptidase A3 remains to be determined.

245   Previous work evaluating mast cell types in horses have investigated lung tissue samples, but not BALF,

246   and reports have been conflicting. A report comparing types in sEAS versus control after moldy hay challenge

247   found no MC_{TC}, although severely asthmatic horses had significantly more MC_C in the wall of the bronchi [31].

248   In conflict to this report, another study found increased tryptase expression in lung tissue from asthmatic horses

249   versus control [32]. BALF IgE-bearing cells have been evaluated in asthmatic horses and were not different

250   from control horses, although this is not mast cell-specific and the exact cell type bearing the IgE was not

251   determined [38]. The current study suggests protease dysregulation, and changes in mast cell type, occur in

252   horses with mastocytic asthma.

253   Both human mast cell types, MC_T and MC_{TC}, are noted to be increased in the lungs of asthmatics

254   compared to control subjects' lungs. Additionally, increased numbers of MC_T in smooth muscle of subjects with

255   asthma have been associated with airway hyper-reactivity [25, 39]. Corticosteroid use specifically decrease

256   MC_T numbers and an increase in MC_{TC} type may be protective of lung function in severe, steroid-dependent

257   human asthmatics [25, 37]. Additional molecular analysis of lung samples revealed that tryptase and

258   carboxypeptidase A3 were among the most differentially expressed genes in asthmatics versus control, with

259   Th2-high asthma associated with expression of tryptase and carboxypeptidase A3, but not chymase [40, 41].

260   This all suggests the importance of mast cell phenotype in asthma type, pathogenesis, and response to therapy.

261   Primary limitations of the study are small sample size, which limits extrapolation of results to other

262   areas of the country, in addition to disease and group classification. Definitions of EAS are continuously

263   changing, with current emphasis placed on clinical signs, BALF cytological examination, and ruling out other

264   causes of lower airway inflammation. Tryptase and chymase are primarily made by mast cells, and although

265   mast cell protease knockout models have suggested a mild decrease in basophil number, suggesting low

266   protease expression; basophils are not noted to be in equine BALF [42-45]. In our study, CD117/c-kit

267   expression increased in maEAS horses and highly correlated with tryptase expression levels, therefore the

268   tryptase gene expression is likely to be of mast cell origin, since basophils do not retain CD117 expression once

269   differentiated [46, 47]. CD117 can also be expressed by other immune cell types, specifically type 2 innate

270   lymphoid cells, however these cells have not yet been described in the horse [48]. It is unclear whether the

271   negative CPA3 amplification in all horses in this study is due to a technical problem with the assay or whether

272   horse BALF mast cells truly do not express CPA3. Carboxypeptidase A3 expression in horses warrants further

273   investigation.

274   Additionally, there is the possibility that the variations in the method of BALF collection, such as the

275   location sampled or volume of return could have influenced cytokine results. Unfortunately, there is not a

276   universally accepted way to normalize the cytokine/chemokine concentrations obtained in BALF recovered

277   across patients. To mitigate this variability, we performed BALF collections in a standardized fashion with

278   standardized fluid volumes infused. Normalization of analyte concentration to fluid volume recovered during

279   the BAL procedure has been recommended, but is not consistently employed in the literature [49].

280   We propose that further, larger sample size evaluation of protease and cytokine/chemokine profiles will

281   identify biomarkers that support defining equine asthma subtypes based on BALF cellular infiltrate, including

282   eosinophilic mild/moderate asthma (emEAS), mastocytic mild/moderate asthma (maEAS), and severe asthma

283   (sEAS). These groups likely have differences that will require specific environmental management and

284   treatments for optimal management of the patient. Lung function tests would be additional useful information

285   for support of specific treatments. A staging scale for severe asthma could be used in addition to, or substitution

286   of, lung function tests, but a staging scale for mEAS does not exist at this time [50].

287   In conclusion, this study demonstrates that, similar to human patients with asthma, horses with mEAS or

288   sEAS have increases in CXCL8 and TNFα, with IFNγ additionally separating sEAS from other groups. In

289   addition, as seen in humans with Th2-high asthma, maEAS is associated with an increase in tryptase and

290   decrease in chymase. Therefore, horses may serve as a naturally-occurring model of human asthma and

291   potential model for chymase dysregulation.

292

Methods

294   *Main study population – (UT-CVM)*

295   Horses were enrolled from the institution's equine hospital caseload and research herd from February

296   2018 to April 2019. The procedures were approved by the University of Tennessee Institutional Animal Care

297   and Use Committee (protocol 2533). Horses from the clinical caseload were enrolled on a volunteer basis with

298   written, informed owner consent, and completed standardized questionnaire.

299   **Table 1** contains the diagnostic criteria for each experimental group, in part defined using consensus

300   guidelines [1]. Attending large animal internal medicine clinicians at the time of client-owned horse enrollment

301   evaluated the horses. The institution's research herd was evaluated by the same two investigators for all horses

302   (JW and CS). Exclusion criteria included horses less than one year of age, history of systemic or respiratory

303   disease (besides suspected asthma) in the past three months, and corticosteroid (systemic or intranasal)

304   administration begun or significant dosage changes within two weeks of enrollment. All horses underwent

305   evaluation via history and physical exam, including a rebreathing exam, CBC/fibrinogen measurement, and

306   BALF cytology. Horses were excluded from analysis if they did not meet final inclusion criteria.

307   *Sub-population – (NCSU-CVM)*

308   As data collection progressed and BALF results of the UT-CVM horses were evaluated, it was observed

309   that no horses with $\geq$ 1% mast cells were enrolled. Therefore, additional equine BALF samples were obtained

310   from a collaborator (KS) at NCSU-CVM, who had previously identified horses with mastocytic asthma

311   (maEAS). These additional samples were used for investigation of mast cell protease mRNA expression

312   because this parameter could be normalized by using standardized quantities of cDNA. The NCSU-CVM

313   samples were processed separately from the remainder of the samples and are identified as a sub-population

314   (**see Table 1**).

315

316   *Sample collection*

317   Main Population (UT-CVM)

318   Blood was collected from the jugular vein into K_2EDTA tubes (Becton, Dickson, and Co., Franklin

319   Lakes, NJ) prior to sedation and was submitted to the institution's clinical pathology laboratory for CBC

320   determination using an Advia 2120i hematology instrument (Siemens Healthcare Diagnostics, Inc.m Tarrytown,

321   NY) and heat-precipitated fibrinogen measurement using an analogue Goldberg TS meter clinical refractometer

322   (Reichert Technologies, Buffalo, NY) by a licensed medical technologist.

323   Bronchoalveolar lavage procedure was performed on standing, sedated horses using a blind technique

324   with a BAL catheter (Mila International, Florence, KY). Sedation for each horse was determined by the

325   attending clinician and consisted of xylazine (0.2 – 0.5 mg/kg) or detomidine (5 - 10 µg/kg), combined with

326   butorphanol (10 – 20 µg/kg) IV. The BAL catheter was passed nasotracheally until wedged. Once wedged, the

327   cuff was inflated and 200 mL of sterile saline was infused and re-aspirated by 60 mL syringe. The first 10 mL

328   of aspirated sample was discarded, with subsequent BALF collected and pooled for analysis.

329   Sub-Population (NCSU-CVM)

330   BAL fluid was collected in a similar manner, with the exception of a larger infusion volume. Following

331   sedations with detomidine (0.005 – 0.01 mg/kg IV) and butorphanol (0.02 – 0.04 mg/kg IV), a cuffed catheter

332   (Bivona, outside diameter 11 mm, 244 cm length, Smith Medical) was passed nasotracheally until wedged. The

333   cuff was then inflated and 300 mL of warmed sterile saline solution was infused and re-aspirated by 60 mL

334   syringe, 150 mLs at a time. The aspirated fluid was pooled, placed on ice and processed within 30 minutes of

335   collection. Of the recovered fluid, 10 mL was submitted to NCSU's Clinical Pathology Service for a total

336   nucleated cell count and 300 cell differential cell count performed by blinded clinical pathologists. Slides were

337   prepared within 2 hours of sample collection, and both direct smear and cytocentrifuge slides were examined.

338   The remaining fluid was filtered to remove mucous and centrifuged to collect the cell pellet. Aliquots were

339   stored at -80°C until further analysis.

340

341   *BALF Cell Count and Cytologic Analysis (UT-CVM)*

342   BALF clinicopathologic analysis consisted of a TNCC and cytologic examination of cytocentrifuged

343   BALF. To optimize preservation of cell morphology, BALF was placed in K_2EDTA tubes for TNCC and

344   cytologic evaluation.

345   TNCC was performed using a scil Vet ABC hematology analyzer (scil animal care, Gurnee, IL) by a

346   trained laboratory assistant or medical technologist. The WBC reported by the instrument was reported as

347   TNCC. To prepare BALF for TNCC, 200 µL of well-mixed BALF was placed into a previously prepared

348   hyaluronidase-containing cryo tubes, in order to break down any mucus that could clog the instrument. All

349   TNCC measurements were done in duplicate to mitigate measurement imprecision, and average of the duplicate

350   TNCC was reported.

351   For cytologic evaluation, 100µL of well-mixed BALF was placed in a cytocentrifuge (Aerospray 7120

352   Slide Stainer and Cytocentrifuge, Wescor Incorporated, Logan UT). Cytocentrifuged specimens were air-dried

353   and stained with aqueous Wright's stain. Nucleated cell differential counting (minimum of 100 cells) was

354   performed by the pathologist on duty and reported as cell type percentages; respiratory epithelial cells were

355   excluded from these differential counts.

356

357   *BALF Preparation for RNA and Cytokine Analysis (UT-CVM)*

358   Pooled BALF placed in non-K_2EDTA tubes was refrigerated at 4°C until further processing, within two

359   hours of collection. To prepare specimens for cytokine and RNA analysis, BALF was strained through sterile

360   4x4 gauze, followed by a 70 µm nylon cell strainer to remove mucus, and then centrifuged. Aliquots of

361   supernatant were made and stored at -80°C until further analysis. Cell pellets were washed two additional times

362   and were stored dry at -80°C until further processing.

363

RNA extraction and gene expression (UT and NCSU-CVM)

364

365   For the main population, RNA was extracted from BALF cell pellets using RNeasy Plus Mini Kit

366   (Qiagen, Hilden, Germany) per manufacturer instructions. For the sub-population, RNA was isolated using an

367   RNeasy Mini Kit with the addition of RNase-free DNase kit (Qiagen) per manufacturer's instructions. The

368   isolated RNA samples were stored at -80°C for up to 18 months.

369   For both populations, quantification and purity of RNA extracted was assessed via NanoDrop 2000c

370   Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). RNA integrity was analyzed on a subset of

371   samples using 2100 Bioanalyzer and the RNA 6000 Nano kit (Agilent, Santa Clara, CA). Reverse transcription

372   and cDNA synthesis was performed on 200ng of RNA using Maxima First Strand cDNA synthesis kit (Thermo

373   Fisher Scientific) and stored at -80°C. Taqman Gene Expression Assays were used for all target genes; β-actin,

374   CD117 (or ckit), tryptase, chymase (CMA1), carboxypeptidase A3 (CPA3), Tgfβ1, & BMP7 (Applied

375   Biosystems, Foster City, CA) (see **Supplementary Table S7**). Real time PCR was performed on 10ng cDNA,

376   with Taqman Fast Advanced Master Mix (Applied Biosystems). QuantStudio 6 Flex Real-Time PCR system

377   (Applied Biosystems) was used for thermal cycling at recommended settings. Results were normalized to β-

378   actin and relative quantification was performed using $2^{-\Delta\Delta Ct}$ method. Results from plates run were used when β-

379   actin standard deviations were ≤ 0.7. Average standard deviation of all plates run was 0.55.

380

Multiplex Bead Immunoassay Analysis (UT-CVM)

381

382   Previously collected BALF supernatant was thawed at room temperature, then hyper-centrifuged to

383   remove any precipitates formed during thawing. Cytokines/chemokines included in the assay were: IL-2, IL-4,

384   IL-5, IL-17A, CXCL8, IFNγ, and TNFα. Cytokine concentrations were quantified using an equine-specific

385   Milliplex® Map Magnetic Bead Panel (EMD Millipore, St Louis, MO, USA) according to the manufacturer's

386   instructions using a Luminex® 200 instrument and Luminex xPONENT® software run in duplicate (Luminex,

387   Austin, TX, USA). Dilutional linearity and percent recovered were determined using low-cytokine containing

388   BALF spiked with kit standard.

389   Data analysis was done using Milliplex Analyst v5.1 software (EMD Millipore). A bead count of at least

390   50 beads per well was used for inclusion in analysis and individual samples with a coefficient of variation (CV)

391   > 15% were not included. The Analyst® software assigned the lowest detectable concentration for the

392   individual analytes in which the cytokine/chemokine concentrations fell below the lower limit of detection

393   (LLOD) of the assay. Best fit standard curve for each analyte was used to calculate analyte concentrations.

394

395   *Statistical analysis*

396   Normality of data was assessed using Shapiro-Wilk test. Descriptive data are expressed as median with

397   interquartile range for both normal and non-normally distributed data for consistency. Descriptive data, protease

398   expression, and cytokine concentrations were analyzed using one-way analysis of variance with Tukey's

399   multiple comparisons in normally distributed data, and by Kruskall-Wallis with Dunn's multiple comparisons in

400   non-normally distributed data. Pairwise correlation of variables including age, sex, cell percentages, gene

401   expression fold changes, and cytokine concentrations was performed, with additional multidimensional scaling

402   (MDS) analysis in order to visualize on a two-dimensional figure the clustering of samples based on age, sex,

403   gene expression fold changes, cytokine concentrations, and neutrophil percentage. Since cell percentages add up

404   to 100, the percentage of only one cell type was used in the clustering to avoid spurious signal driven by cell

405   percentages going in opposite directions. Bray-Curtis distance function was applied to calculate the dissimilarity

406   matrix of dataset, which ignored missing gene expression values in 5 samples. To evaluate which variable

407   contribute the most to sample clustering, an additional principal components analysis (PCA, which is a specific

408   solution of MDS based on Euclidean distance of complete data) on the samples with no missing values was

409   performed, followed by quantification of the contributions of each variable to the first two principal

410   components. Significance was set at $p \leq 0.05$.

411

References

1. Couetil, L.L., et al., *Inflammatory Airway Disease of Horses--Revised Consensus Statement.* J Vet Intern Med, 2016. **30**(2): p. 503-15.
2. Pirie, R.S., *Recurrent airway obstruction: a review.* Equine Vet J, 2014. **46**(3): p. 276-88.
3. Hotchkiss, J.W., S.W. Reid, and R.M. Christley, *A survey of horse owners in Great Britain regarding horses in their care. Part 2: Risk factors for recurrent airway obstruction.* Equine Vet J, 2007. **39**(4): p. 301-8.
4. Davis, K.U. and M.K. Sheats, *Bronchoalveolar Lavage Cytology Characteristics and Seasonal Changes in a Herd of Pastured Teaching Horses.* Front Vet Sci, 2019. **6**: p. 74.
5. Bond, S., et al., *Equine asthma: Integrative biologic relevance of a recently proposed nomenclature.* J Vet Intern Med, 2018. **32**(6): p. 2088-2098.
6. Hughes, K.J., et al., *Evaluation of cytokine mRNA expression in bronchoalveolar lavage cells from horses with inflammatory airway disease.* Vet Immunol Immunopathol, 2011. **140**(1-2): p. 82-9.
7. Lavoie, J.P., et al., *Bronchoalveolar lavage fluid cytology and cytokine messenger ribonucleic Acid expression of racehorses with exercise intolerance and lower airway inflammation.* J Vet Intern Med, 2011. **25**(2): p. 322-9.
8. Beekman, L., T. Tohver, and R. Leguillette, *Comparison of cytokine mRNA expression in the bronchoalveolar lavage fluid of horses with inflammatory airway disease and bronchoalveolar lavage mastocytosis or neutrophilia using REST software analysis.* J Vet Intern Med, 2012. **26**(1): p. 153-61.
9. Richard, E.A., et al., *Cytokine concentrations in bronchoalveolar lavage fluid from horses with neutrophilic inflammatory airway disease.* J Vet Intern Med, 2014. **28**(6): p. 1838-44.
10. Montgomery, J.B., et al., *Tumor necrosis factor-alpha protein concentrations in bronchoalveolar lavage fluid from healthy horses and horses with severe equine asthma.* Vet Immunol Immunopathol, 2018. **202**: p. 70-73.
11. Giguere, S., et al., *Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate.* Vet Immunol Immunopathol, 2002. **85**(3-4): p. 147-58.
12. Lavoie, J.P., et al., *Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile.* Am J Respir Crit Care Med, 2001. **164**(8 Pt 1): p. 1410-3.
13. Debrue, M., et al., *Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells.* Vet Immunol Immunopathol, 2005. **105**(1-2): p. 25-31.
14. Padoan, E., et al., *Real time RT-PCR analysis of inflammatory mediator expression in recurrent airway obstruction-affected horses.* Vet Immunol Immunopathol, 2013. **156**(3-4): p. 190-9.
15. Tessier, L., et al., *Impaired response of the bronchial epithelium to inflammation characterizes severe equine asthma.* BMC Genomics, 2017. **18**(1): p. 708.
16. Bond, S.L., J. Hundt, and R. Leguillette, *Effect of injected dexamethasone on relative cytokine mRNA expression in bronchoalveolar lavage fluid in horses with mild asthma.* BMC Vet Res, 2019. **15**(1): p. 397.
17. Hansen, S., et al., *Bronchoalveolar lavage fluid cytokine, cytology and IgE allergen in horses with equine asthma.* Vet Immunol Immunopathol, 2019. **220**: p. 109976.
18. Stumm, C.L., et al., *Lung remodeling in a mouse model of asthma involves a balance between TGF-beta1 and BMP-7.* PLoS One, 2014. **9**(4): p. e95959.
19. Pegorier, S., et al., *Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF).* Respir Res, 2010. **11**: p. 85.
20. Kariyawasam, H.H., et al., *Basal expression of bone morphogenetic protein receptor is reduced in mild asthma.* Am J Respir Crit Care Med, 2008. **177**(10): p. 1074-81.
21. Desjardins, I., et al., *Comparison of TGF-beta 1 concentrations in bronchoalveolar fluid of horses affected with heaves and of normal controls.* Vet Immunol Immunopathol, 2004. **101**(3-4): p. 133-41.

461 22. Sheats, M.K., K.U. Davis, and J.A. Poole, *Comparative Review of Asthma in Farmers and Horses.* Curr
462   Allergy Asthma Rep, 2019. **19**(11): p. 50.
463 23. Bullone, M. and J.P. Lavoie, *Asthma "of horses and men"--how can equine heaves help us better*
464   *understand human asthma immunopathology and its functional consequences?* Mol Immunol, 2015.
465   **66**(1): p. 97-105.
466 24. Leclere, M., A. Lavoie-Lamoureux, and J.P. Lavoie, *Heaves, an asthma-like disease of horses.*
467   Respirology, 2011. **16**(7): p. 1027-46.
468 25. Balzar, S., et al., *Mast cell phenotype, location, and activation in severe asthma. Data from the Severe*
469   *Asthma Research Program.* Am J Respir Crit Care Med, 2011. **183**(3): p. 299-309.
470 26. Wang, G., et al., *Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma.*
471   Eur Respir J, 2016. **47**(4): p. 1123-33.
472 27. Berthon, B.S., et al., *A sputum gene expression signature predicts oral corticosteroid response in*
473   *asthma.* Eur Respir J, 2017. **49**(6).
474 28. Irani, A.A., et al., *Two types of human mast cells that have distinct neutral protease compositions.* Proc
475   Natl Acad Sci U S A, 1986. **83**(12): p. 4464-8.
476 29. Irani, A.M., et al., *Human mast cell carboxypeptidase. Selective localization to MCTC cells.* J Immunol,
477   1991. **147**(1): p. 247-53.
478 30. Beil, W.J. and J. Pammer, *In situ detection of the mast cell proteases chymase and tryptase in human*
479   *lung tissue using light and electron microscopy.* Histochem Cell Biol, 2001. **116**(6): p. 483-93.
480 31. van der Haegen, A., et al., *Mast cells and IgE-bearing cells in lungs of RAO-affected horses.* Vet
481   Immunol Immunopathol, 2005. **108**(3-4): p. 325-34.
482 32. Dacre, K.J., et al., *Organic dust exposure increases mast cell tryptase in bronchoalveolar lavage fluid*
483   *and airway epithelium of heaves horses.* Clin Exp Allergy, 2007. **37**(12): p. 1809-18.
484 33. Raundhal, M., et al., *High IFN-gamma and low SLPI mark severe asthma in mice and humans.* J Clin
485   Invest, 2015. **125**(8): p. 3037-50.
486 34. Hosoki, K., et al., *Analysis of a Panel of 48 Cytokines in BAL Fluids Specifically Identifies IL-8 Levels*
487   *as the Only Cytokine that Distinguishes Controlled Asthma from Uncontrolled Asthma, and Correlates*
488   *Inversely with FEV1.* PLoS One, 2015. **10**(5): p. e0126035.
489 35. Yang, T., et al., *Characteristics of Proinflammatory Cytokines and Chemokines in Airways of*
490   *Asthmatics: Relationships with Disease Severity and Infiltration of Inflammatory Cells.* Chin Med J
491   (Engl), 2017. **130**(17): p. 2033-2040.
492 36. Waern, I., et al., *Mast cell chymase modulates IL-33 levels and controls allergic sensitization in dust-*
493   *mite induced airway inflammation.* Mucosal Immunol, 2013. **6**(5): p. 911-20.
494 37. Balzar, S., et al., *Relationship of small airway chymase-positive mast cells and lung function in severe*
495   *asthma.* Am J Respir Crit Care Med, 2005. **171**(5): p. 431-9.
496 38. Kunzle, F., et al., *IgE-bearing cells in bronchoalveolar lavage fluid and allergen-specific IgE levels in*
497   *sera from RAO-affected horses.* J Vet Med A Physiol Pathol Clin Med, 2007. **54**(1): p. 40-7.
498 39. Brightling, C.E., et al., *Mast-cell infiltration of airway smooth muscle in asthma.* N Engl J Med, 2002.
499   **346**(22): p. 1699-705.
500 40. Dougherty, R.H., et al., *Accumulation of intraepithelial mast cells with a unique protease phenotype in*
501   *T(H)2-high asthma.* J Allergy Clin Immunol, 2010. **125**(5): p. 1046-1053.e8.
502 41. Woodruff, P.G., et al., *Genome-wide profiling identifies epithelial cell genes associated with asthma and*
503   *with treatment response to corticosteroids.* Proc Natl Acad Sci U S A, 2007. **104**(40): p. 15858-63.
504 42. Heutinck, K.M., et al., *Serine proteases of the human immune system in health and disease.* Mol
505   Immunol, 2010. **47**(11-12): p. 1943-55.
506 43. Pejler, G., et al., *Mast cell proteases.* Adv Immunol, 2007. **95**: p. 167-255.
507 44. Pejler, G., et al., *Mast cell proteases: multifaceted regulators of inflammatory disease.* Blood, 2010.
508   **115**(24): p. 4981-90.
509 45. Reber, L.L., T. Marichal, and S.J. Galli, *New models for analyzing mast cell functions in vivo.* Trends
510   Immunol, 2012. **33**(12): p. 613-25.

46.   Han, X., et al., *Immunophenotypic study of basophils by multiparameter flow cytometry.* Arch Pathol Lab Med, 2008. **132**(5): p. 813-9.

47.   Galli, S.J., M. Tsai, and B.K. Wershil, *The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.* Am J Pathol, 1993. **142**(4): p. 965-74.

48.   Hochdorfer, T., et al., *Expression of c-Kit discriminates between two functionally distinct subsets of human type 2 innate lymphoid cells.* Eur J Immunol, 2019. **49**(6): p. 884-893.

49.   Haslam, P.L. and R.P. Baughman, *Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL.* Eur Respir J, 1999. **14**(2): p. 245-8.

50.   Simoes, J., J. Sales Luis, and P. Tilley, *Contribution of lung function tests to the staging of severe equine asthma syndrome in the field.* Res Vet Sci, 2019. **123**: p. 112-117.

Acknowledgements

Author Contributions

J.S.W. and E.M.L. conceived the project. J.S.W., M.H., C.S., B.F., and E.M.L. planned the study design. J.S.W. collected and processed samples, performed gene expression and cytokine analysis, analyzed data, and wrote the first draft of the manuscript. B.F. optimized TNCC procedures and provided guidance on clinicopathologic data. M.H., C.S., M.H., and J.S.W. collected UT-CVM samples, and K.D. and M.K.S. collected NCSU samples and extracted RNA. J.S.W. processed all UT-CVM samples. M.H., C.S., B.F., and E.M.L. edited grant proposals for the support of this research. Y.L. and P.W. performed advanced statistical analysis and associated manuscript figures. J.S.W. and E.M.L. created all other manuscript figures. E.M.L. supervised J.S.W. and edited all drafts of the manuscript. M.H., C.S., B.F., K.D., M.K.S., Y.L, and P.W. edited manuscript. All the authors have read and approved the final manuscript.

Additional Information

The author(s) declare no competing interests.

541

Figure Legends

Figure 1. Relative gene expression level of (a) CD117 (*ckit*), (b) tryptase (*tpsb2*), and (c) chymase (*cma1*) in BALF cell pellets in healthy (n = 11), mild/moderate asthma (n = 8), severe asthma (n = 10), and mastocytic asthma (n = 8). All target genes were normalized to the house keeping gene β-actin (*actb*). Displayed figures represent the mean with SEM. sEAS= Severe Asthma, mEAS= Mild/Moderate Asthma, Ctr= Healthy, maEAS= Mastocytic Asthma. *, $p < 0.05$.

Figure 2. Cytokine concentrations of (a) TNFα, (b) CXCL8/IL-8, and (c) IFNɣ measured via multiplex bead immunoassay in healthy (n=11), mild/moderate asthma (n = 9), and severe asthma (n = 14). Displayed figures represent the mean with SEM. sEAS= Severe Asthma, mEAS= Mild/Moderate Asthma, Ctr= Healthy. *, $p < 0.05$; **, $p < 0.01$; ***, $p < .001$; **** $p < 0.0001$.

Figure 3. Pairwise correlation of variable. Only significant ($p < 0.05$) correlations are shown. The size of the circle represents the strength of the correlation, and the color represents directionality. The variables are hierarchically clustered based on their correlations.

Figure 4. (a) Multidimensional scaling of the samples based on age, sex, cell percentages, gene expression fold changes, and cytokine concentrations. Each sample is labeled with its anonymous numeric identifier. Asthma status is indicated by gray scale and symbol. (b) The maximum contribution to first two principal components from each variable, which shows the relative importance of each variable in driving the observed clustering pattern. The first two principal components explained over 98.5% of the variance in the data.

Figure 5. Relative gene expression level of (a) *bmp7*, (b) *tgfβ1*, (c) *tgfβ1/ bmp7* in BALF cell pellets. Sample size of (a) and (b), healthy: n=11, mild/moderate asthma: n = 8, severe asthma: n = 10 (BMP7 low = 4 & BMP7

566 high = 6), and mastocytic asthma: n = 7. Sample size of (c) and (d), healthy: n=10, mild/moderate asthma: n =

567 8, severe asthma: n = 7, and mastocytic asthma: n = 7. sEAS= Severe Asthma, mEAS= Mild/Moderate Asthma,

568 Ctr= Healthy, maEAS= Mastocytic Asthma. *, p<0.05; **, p<0.01.

569

570 **Table Legends**

571

572 **Table 2.** Bronchoalveolar lavage fluid characteristics for the four defined groups: TNCC, Neutrophil %,

573 Lymphocyte %, Macrophage %, Eosinophil %, and Mast cell %. Data are expressed as median [IQR]. sEAS,

574 n=14; mEAS, n=9; Ctr, n=11; maEAS, n=8.

575

576

577 **Table 3.** Median cytokine concentrations of IL-5, IL-17A, IL-2, IL-4, IFNɣ, CXCL8, and TNFα measured via

578 multiplex bead immunoassay in healthy (n=11), mild/moderate asthma (n = 9), and severe asthma (n = 14).

579 sEAS= Severe Asthma, mEAS= Mild/Moderate Asthma, Ctr= Healthy. Data are expressed as median [IQR].

580

581

582

583

584